Lithuanian biotech start-up Exolitus certified as a leader in the Baltic region

  • 2023-01-27

Extracellular vesicles, or in short EVs, are thought to be the next big thing that will revolutionise the pharmaceutical and cosmeceutical industries. One of the emerging global players is Lithuanian start-up biotechnology company UAB Exolitus, recently certified as an "A "class leader in its business sector in the Baltic region and strongest in Lithuania by monitoring companies Okredo and Creditinfo.   

So why are EVs so important? "Because they are critical elements of cell communication!" - all the members of Exolitus confirm without hesitation. "Cell therapy has been widely discussed in society lately; however, not many people know that the therapy is efficient because of EVs,”  Exolitus process manager Zbigniev adds.  

Most living cells secrete EVs, and we can find them in all body fluids, such as blood, saliva, and milk, as well as in fresh and dry plant material. EVs are nanoscale membrane-wrapped messengers that contain bioactive substances. "It is incredible that by purifying EVs from such well-known source materials as milk or plants, we obtain entirely new substances with such a solid bioactive potential. The power of EVs inspires and motivates me to learn more about them," Emilija joyfully shares. She is a new member of the team who recently started her EU-funded industrial PhD at Exolitus.

"The interest in our products and services is constantly growing; our clients are pharmaceutical and cosmetics companies, beauty clinics, and scientists. Most of them become passionate about EVs when they discover more about them; it is nice to see how the EV hub is growing," marketing manager Justina says.

"Indeed, the capacity of EVs is far from explored and even further from exploited,"  admits Aiste, Exolitus CEO. "We are at the dawn of breakthroughs, and EVs are at their core. These tiny vesicles offer life-saving solutions; they can cure cancer and neurodegenerative disorders, restore organ functions, heal wounds and remove scars. We are very proud to work in this field and to expand the development of the cell biotechnology sector in our country."